Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Total Therapy 2 examined the clinical benefit of adding thalidomide up-front to a tandem transplant regimen for newly diagnosed patients with multiple myeloma. When initially reported with a median follow-up of 42 months, complete response rate and event-free survival were superior among the 323 pat...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Barlogie, Bart, Pineda-Roman, Mauricio, van Rhee, Frits, Haessler, Jeff, Anaissie, Elias, Hollmig, Klaus, Alsayed, Yazan, Waheed, Sarah, Petty, Nathan, Epstein, Joshua, Shaughnessy, John D., Tricot, Guido, Zangari, Maurizio, Zeldis, Jerome, Barer, Sol, Crowley, John
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2008
Предметы:
Clinical Trials and Observations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2569166/
https://ncbi.nlm.nih.gov/pubmed/18492953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-03-145235
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы